Logo image of CYRX

CRYOPORT INC (CYRX) Stock Fundamental Analysis

USA - NASDAQ:CYRX - US2290503075 - Common Stock

10.01 USD
-0.12 (-1.18%)
Last: 9/23/2025, 11:11:10 AM
Fundamental Rating

4

CYRX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. CYRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CYRX has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

CYRX had positive earnings in the past year.
CYRX had a negative operating cash flow in the past year.
In the past 5 years CYRX always reported negative net income.
CYRX had negative operating cash flow in 4 of the past 5 years.
CYRX Yearly Net Income VS EBIT VS OCF VS FCFCYRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

CYRX's Return On Assets of 8.70% is amongst the best of the industry. CYRX outperforms 85.71% of its industry peers.
CYRX has a Return On Equity of 13.06%. This is amongst the best in the industry. CYRX outperforms 85.71% of its industry peers.
Industry RankSector Rank
ROA 8.7%
ROE 13.06%
ROIC N/A
ROA(3y)-11.01%
ROA(5y)-14.42%
ROE(3y)-20.23%
ROE(5y)-24.9%
ROIC(3y)N/A
ROIC(5y)N/A
CYRX Yearly ROA, ROE, ROICCYRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

Looking at the Profit Margin, with a value of 33.22%, CYRX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Looking at the Gross Margin, with a value of 45.73%, CYRX is in line with its industry, outperforming 46.43% of the companies in the same industry.
CYRX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 33.22%
GM 45.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y-3.2%
CYRX Yearly Profit, Operating, Gross MarginsCYRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

CYRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CYRX has been increased compared to 5 years ago.
The debt/assets ratio for CYRX has been reduced compared to a year ago.
CYRX Yearly Shares OutstandingCYRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CYRX Yearly Total Debt VS Total AssetsCYRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

CYRX has an Altman-Z score of 0.73. This is a bad value and indicates that CYRX is not financially healthy and even has some risk of bankruptcy.
CYRX has a Altman-Z score of 0.73. This is in the lower half of the industry: CYRX underperforms 62.50% of its industry peers.
CYRX has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.36, CYRX perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Altman-Z 0.73
ROIC/WACCN/A
WACC8.68%
CYRX Yearly LT Debt VS Equity VS FCFCYRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 16.24 indicates that CYRX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 16.24, CYRX belongs to the top of the industry, outperforming 96.43% of the companies in the same industry.
CYRX has a Quick Ratio of 15.47. This indicates that CYRX is financially healthy and has no problem in meeting its short term obligations.
CYRX's Quick ratio of 15.47 is amongst the best of the industry. CYRX outperforms 96.43% of its industry peers.
Industry RankSector Rank
Current Ratio 16.24
Quick Ratio 15.47
CYRX Yearly Current Assets VS Current LiabilitesCYRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

CYRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 156.84%, which is quite impressive.
Looking at the last year, CYRX shows a very negative growth in Revenue. The Revenue has decreased by -10.16% in the last year.
CYRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 46.45% yearly.
EPS 1Y (TTM)156.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%806.9%
Revenue 1Y (TTM)-10.16%
Revenue growth 3Y0.86%
Revenue growth 5Y46.45%
Sales Q2Q%-21.08%

3.2 Future

The Earnings Per Share is expected to grow by 12.23% on average over the next years. This is quite good.
CYRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.14% yearly.
EPS Next Y69.7%
EPS Next 2Y17.13%
EPS Next 3Y12.46%
EPS Next 5Y12.23%
Revenue Next Year-24.93%
Revenue Next 2Y-9.5%
Revenue Next 3Y-4.03%
Revenue Next 5Y0.14%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CYRX Yearly Revenue VS EstimatesCYRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M
CYRX Yearly EPS VS EstimatesCYRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -0.5 -1 -1.5 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 7.53 indicates a rather cheap valuation of CYRX.
Compared to the rest of the industry, the Price/Earnings ratio of CYRX indicates a rather cheap valuation: CYRX is cheaper than 100.00% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of CYRX to the average of the S&P500 Index (27.41), we can say CYRX is valued rather cheaply.
CYRX is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 7.53
Fwd PE N/A
CYRX Price Earnings VS Forward Price EarningsCYRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYRX Per share dataCYRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

CYRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CYRX's earnings are expected to grow with 12.46% in the coming years.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y17.13%
EPS Next 3Y12.46%

More info and screens

0

5. Dividend

5.1 Amount

CYRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRYOPORT INC

NASDAQ:CYRX (9/23/2025, 11:11:10 AM)

10.01

-0.12 (-1.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners98.37%
Inst Owner Change-1.08%
Ins Owners3.83%
Ins Owner Change21.34%
Market Cap501.20M
Analysts85.33
Price Target12.35 (23.38%)
Short Float %5.74%
Short Ratio3.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)484.77%
Min EPS beat(2)12.27%
Max EPS beat(2)957.28%
EPS beat(4)3
Avg EPS beat(4)255.58%
Min EPS beat(4)-40.53%
Max EPS beat(4)957.28%
EPS beat(8)5
Avg EPS beat(8)86.3%
EPS beat(12)6
Avg EPS beat(12)50.61%
EPS beat(16)7
Avg EPS beat(16)31.23%
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-5.29%
Max Revenue beat(2)6.79%
Revenue beat(4)1
Avg Revenue beat(4)-0.77%
Min Revenue beat(4)-5.29%
Max Revenue beat(4)6.79%
Revenue beat(8)1
Avg Revenue beat(8)-2.29%
Revenue beat(12)2
Avg Revenue beat(12)-3.23%
Revenue beat(16)3
Avg Revenue beat(16)-2.94%
PT rev (1m)12.01%
PT rev (3m)10.66%
EPS NQ rev (1m)-1.05%
EPS NQ rev (3m)0.89%
EPS NY rev (1m)0%
EPS NY rev (3m)66.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.96%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)0.8%
Valuation
Industry RankSector Rank
PE 7.53
Fwd PE N/A
P/S 2.47
P/FCF N/A
P/OCF N/A
P/B 0.97
P/tB 1.42
EV/EBITDA N/A
EPS(TTM)1.33
EY13.29%
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS4.05
BVpS10.29
TBVpS7.05
PEG (NY)0.11
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 8.7%
ROE 13.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 33.22%
GM 45.73%
FCFM N/A
ROA(3y)-11.01%
ROA(5y)-14.42%
ROE(3y)-20.23%
ROE(5y)-24.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y-3.2%
F-Score5
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.5%
Cap/Sales 10.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.24
Quick Ratio 15.47
Altman-Z 0.73
F-Score5
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)112.93%
Cap/Depr(5y)112.05%
Cap/Sales(3y)12.92%
Cap/Sales(5y)12.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)156.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%806.9%
EPS Next Y69.7%
EPS Next 2Y17.13%
EPS Next 3Y12.46%
EPS Next 5Y12.23%
Revenue 1Y (TTM)-10.16%
Revenue growth 3Y0.86%
Revenue growth 5Y46.45%
Sales Q2Q%-21.08%
Revenue Next Year-24.93%
Revenue Next 2Y-9.5%
Revenue Next 3Y-4.03%
Revenue Next 5Y0.14%
EBIT growth 1Y33.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.19%
EBIT Next 3Y27.15%
EBIT Next 5Y18.38%
FCF growth 1Y-17.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-597.62%
OCF growth 3YN/A
OCF growth 5YN/A